Synergistically combines the complementary clinical effects of PRP and HA to provide added benefit for OA patients.

A-PRP: The patient’s platelet concentrate prepared with Cellular Matrix, provides an autologous reservoir of growth factors.

CellularMatrix A-CP-HA – Medical Device Class III – CE2797. Fully license to used as combination therapeutic, Cellular Matrix is a cell-friendly network that contains 2ml of HA at a concentration of 20mg/ml (40mg total), in addition to the thixotropic cell-separation gel and the sodium citrate anticoagulant solution.